Department of Urology, Division of Transplantation, University of Miami, Miller School of Medicine, Miami, FL.
Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.
Written by:
Gorin MA, Ekwenna O, Soloway MS, Ciancio G. Are you the author?
Reference: Urology. 2011 Jun 13. Epub ahead of print.
doi: 10.1016/j.urology.2011.04.018
PubMed Abstract
PMID: 21676439
UroToday.com Renal Cancer Section
